Daniel M. Schmitt
CEO, President & DirectorMr. Daniel M. Schmitt, also known as Dan, serves as Chief Executive Officer and President at Actuate Therapeutics, Inc. since March 2015. Mr. Schmitt served as Chief Operating Officer of Genus Oncology, LLC from 2009 to 2014. Mr. Schmitt served as Senior Vice President of Licensing and Commercial Development at Immtech Pharmaceuticals (AMEX: IMM) Inc. from 2004 to 2009. He served as General Manager, Academic and Government Institutional Markets at First Genetic Trust (FGT) from 2001 to 2004. He previously held positions with G.D. Searle Inc., a pharmaceutical company, ILEX Oncology, Inc., a pharmaceutical company, Fujisawa USA, Inc., a pharmaceutical company and Burroughs Wellcome Co., a pharmaceutical company. He served as Director of Commercial Development at Immtech International Inc. from November 16, 2004 to February 2005 and also served as its Vice President of Licensing & Commercial Development since February 2005. Mr. Schmitt has many years of successful industry experience in operations management, new product development and business development, with roles in both large pharmaceutical and small biotechnology companies. During his career, he has led and contributed to the successful development and launch of multiple pharmaceutical products and has constructed and executed numerous high value licensing, acquisition and development deals for biotech and pharmaceutical companies totaling nearly 1 billion in upfront and potential milestone payments. Prior to joining Immtech, he worked at First Genetic Trust (FGT) as Director of Academic Partnerships. In this capacity, he was responsible for developing collaborations in cutting edge genomic research. Mr. Schmitt was responsible for developing and expanding collaborations with Johns Hopkins University, University of California at Irvine, Howard University, the National Cancer Institute and the International Genomics Consortium. He also led FGT's program to develop NetMEDS, a national consortium of 10 integrated healthcare networks for post marketing surveillance of approved medicines in conjunction with the FDA. Prior to FGT, Mr. Schmitt served as Director of Global Oncology at Searle/Pharmacia, where he headed the teams responsible for developing commercialization strategies for Searle's programs in anti-angiogenesis and immunotherapy, including cancer vaccines. In his role as commercial leader, he was also responsible for the evaluation of new products and technologies for the Searle/Pharmacia oncology portfolio. Mr. Schmitt serves as Director at Actuate Therapeutics, Inc. since April 2015. He also served as an Entrepreneur-In-Residence at Northwestern University in 2014 and as an external expert consultant for both the University of Chicago and the University of Illinois — Chicago from 2011 to 2014. Mr. Schmitt serves as Commercial Development Consultant for University of Chicago s Innovation PEER (Panel of External Expert Reviewers) Program and is a Member of Chicago Innovation Mentors, a collaborative program between Chicago-based entrepreneurs and the University of Chicago, Northwestern University, the University of Illinois, Chicago and iBIO to accelerate the translation of basic research into innovative products and services. Mr. Schmitt received his M.B.A and a B.S. in Chemistry with a concentration in Theoretical Mathematics from West Virginia University and has held research positions affiliated with the National Foundation for Cancer Research in 1984 and at the University of North Carolina School of Medicine from 1987 to 1988.
Positions
- Company NameActuate Therapeutics, Inc.Stock CodeACTUPositionCEO, President & DirectorColleagues
